Introduction: Who Should Seek Diagnostic Testing
ENPP1 deficiency is a rare genetic disorder that can affect people at any age, from before birth through adulthood. Because the disease can present differently depending on when symptoms first appear, knowing when to seek diagnostic testing is crucial for proper care and management.[1]
Infants who show signs of serious health problems such as heart failure, severe high blood pressure, breathing difficulties, or unexplained swelling should be evaluated for ENPP1 deficiency. These babies may have a condition called generalized arterial calcification of infancy, or GACI, which happens when calcium deposits build up in the walls of blood vessels. This buildup can be life-threatening, making rapid diagnosis essential.[1][3]
Children who develop bone problems such as bowing of the legs, weak bones that fracture easily, or poor growth should also be tested. These symptoms may indicate autosomal recessive hypophosphatemic rickets type 2, or ARHR2, which is another form of ENPP1 deficiency that affects bone development. Some children with ARHR2 may have survived the infant stage of GACI, while others may develop bone symptoms without ever having heart or blood vessel problems in infancy.[1][10]
Adults who experience ongoing joint pain, stiffness, hearing loss, or calcifications in tissues around their joints may also have ENPP1 deficiency. These symptoms can significantly affect quality of life and mobility, making diagnosis important even later in life.[1][17]
Because ENPP1 deficiency is inherited in families, siblings of a diagnosed patient should also consider genetic testing, even if they have no symptoms. Early detection allows for monitoring and intervention before serious complications develop. Parents who have one child with ENPP1 deficiency may want to discuss genetic counseling and testing for future pregnancies.[4]
Classic Diagnostic Methods
Diagnosing ENPP1 deficiency involves a combination of clinical observations, imaging studies, blood tests, and genetic analysis. The specific tests used depend on the age of the patient and the symptoms they are experiencing.
Clinical Examination and Medical History
The diagnostic process typically begins with a thorough physical examination and review of the patient’s medical history. Doctors look for visible signs such as bone deformities, short stature, unusual walking patterns, or signs of heart problems. In infants, symptoms like difficulty breathing, poor feeding, or signs of heart failure may prompt further investigation.[1][17]
A family history of similar symptoms or early infant death can provide important clues. Because ENPP1 deficiency is inherited when a person receives mutated genes from both parents, knowing whether parents are carriers or whether other family members are affected helps guide the diagnostic process.[4]
Imaging Studies
Imaging tests play a crucial role in identifying calcifications in blood vessels, soft tissues, and areas around joints. For infants suspected of having GACI, doctors may order chest X-rays or computed tomography scans to look for calcium deposits in the arteries. These deposits appear as bright spots on the images and indicate abnormal mineralization in places where calcium should not accumulate.[1][14]
In children and adults, X-rays of bones may reveal signs of rickets or osteomalacia, which is a softening of the bones. The bones may appear thinner than normal or show evidence of bowing or fractures. Additional imaging around joints can identify calcifications in tendons and ligaments, which cause pain and reduced mobility.[17]
Ultrasound examinations of the heart, called echocardiograms, may be performed to check for heart valve problems or signs of heart failure. This is especially important in infants and young children who have cardiovascular symptoms.[1]
Laboratory Tests
Blood tests are used to measure levels of certain substances that are affected by ENPP1 deficiency. One important test measures the level of phosphate in the blood. People with ARHR2 typically have low phosphate levels, a condition called hypophosphatemia, which contributes to weak and poorly mineralized bones.[3][14]
Another blood test measures a hormone called FGF23, which regulates phosphate levels in the body. In ENPP1 deficiency, FGF23 levels are often elevated, causing the kidneys to lose too much phosphate in the urine. This loss of phosphate worsens bone problems.[14]
Doctors may also measure levels of pyrophosphate, or PPi, in the blood. ENPP1 is the enzyme responsible for producing PPi, which normally prevents calcium from depositing in soft tissues. In people with ENPP1 deficiency, PPi levels are reduced, allowing abnormal calcification to occur.[1][11]
Genetic Testing
The definitive way to diagnose ENPP1 deficiency is through genetic testing. This involves analyzing a blood or saliva sample to look for mutations in the ENPP1 gene. ENPP1 deficiency is caused by biallelic mutations, meaning the person has inherited a mutated gene from each parent. These mutations can be identical, called homozygous, or different, called compound heterozygous.[3][4]
More than 40 different mutations in the ENPP1 gene have been identified in patients with GACI, and many more have been found in people with ARHR2. Genetic testing is typically performed by laboratories certified under the College of American Pathologists and Clinical Laboratory Improvement Amendments, which ensures accuracy and reliability.[3][12]
Some companies and organizations offer no-cost genetic testing programs for ENPP1 and related deficiencies to help families obtain a diagnosis. These programs can be especially helpful for families who might otherwise face financial barriers to testing.[16]
Distinguishing ENPP1 Deficiency from Other Conditions
Because symptoms of ENPP1 deficiency overlap with other disorders, doctors must carefully rule out alternative diagnoses. For example, arterial calcification in infants can also be caused by mutations in the ABCC6 gene, a condition sometimes called GACI Type 2. Genetic testing helps distinguish between these two conditions, which is important because their underlying causes and potential treatments may differ.[7][12]
In older children and adults, rickets caused by ENPP1 deficiency must be differentiated from other forms of rickets, such as those caused by vitamin D deficiency or other genetic mutations affecting phosphate regulation. Blood tests measuring vitamin D, calcium, and phosphate levels, along with genetic testing, help make this distinction.[3]
Diagnostics for Clinical Trial Qualification
Clinical trials are research studies that test new treatments to determine whether they are safe and effective. For patients with ENPP1 deficiency, participating in a clinical trial may offer access to experimental therapies that are not yet available to the general public. However, to qualify for a trial, patients must meet specific diagnostic criteria established by the researchers.[9][12]
Genetic Confirmation
One of the most important requirements for enrollment in ENPP1 deficiency clinical trials is genetic confirmation of the disease. Participants must have documented biallelic mutations in the ENPP1 gene, verified by a certified laboratory. This ensures that everyone in the trial has the same underlying genetic cause for their symptoms, which makes it easier to assess whether a treatment is working.[12][13]
Clinical Manifestations
In addition to genetic confirmation, clinical trials often require evidence of clinical manifestations of the disease. For infant trials, this may include documented calcification in blood vessels, heart failure, high blood pressure, or other cardiovascular complications. Imaging studies such as X-rays, CT scans, or echocardiograms are used to confirm these findings.[12]
For children and adults, trials may require evidence of bone disease such as rickets or osteomalacia, joint or ligament calcifications, or functional impairments like difficulty walking or chronic pain. Blood tests showing low phosphate levels or elevated FGF23 may also be part of the qualification criteria.[13]
Age and Disease Stage
Clinical trials for ENPP1 deficiency are often divided by age group because the disease affects people differently depending on when symptoms begin. Some trials focus on infants from birth to one year of age, while others enroll children aged one to twelve years, or adults over eighteen years. The specific age range depends on the type of treatment being tested and the stage of disease it is intended to address.[12][13]
Baseline Testing and Monitoring
Before starting a clinical trial, participants undergo extensive baseline testing to document their current health status. This may include detailed imaging of blood vessels and bones, blood tests to measure PPi and phosphate levels, assessments of heart and kidney function, and evaluations of mobility and quality of life. These baseline measurements are compared to results obtained during and after treatment to determine whether the therapy is having an effect.[12][13]
Throughout the trial, participants are monitored closely with repeated tests and examinations. This helps researchers track changes in the disease and identify any side effects from the experimental treatment. The frequency and type of monitoring depend on the trial protocol.[13]
Patient Registries and Natural History Studies
In addition to treatment trials, researchers conduct natural history studies and maintain patient registries to better understand how ENPP1 deficiency progresses over time. These studies collect information about symptoms, complications, and patient-reported outcomes during routine medical visits. While they do not test new treatments, they provide valuable data that helps design future trials and improve care.[7][13]
Participation in a registry does not require any additional tests beyond what is already part of standard care, making it an accessible option for many families. Registries also help connect patients with researchers and clinical trial opportunities as they become available.[7]
